Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2006 1
2008 1
2010 1
2011 1
2015 3
2016 1
2019 1
2020 2
2021 3
2022 3
2023 6
2024 3
2025 1
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for m khatibi
Your search for M Khatiban retrieved no results
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators. Oza AM, et al. Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23. Lancet Oncol. 2015. PMID: 26115797 Free PMC article. Clinical Trial.
Eligible adult women with newly diagnosed ovarian cancer that was either high-risk early-stage disease (International Federation of Gynecology and Obstetrics [FIGO] stage I-IIa, grade 3 or clear cell histology) or more advanced disease (FIGO stage IIb-IV), with an Eastern Coopera …
Eligible adult women with newly diagnosed ovarian cancer that was either high-risk early-stage disease (International Federation of Gynecolo …
Body size interacts with the structure of the central nervous system: A multi-center in vivo neuroimaging study.
Labounek R, Bondy MT, Paulson AL, Bédard S, Abramovic M, Alonso-Ortiz E, Atcheson NT, Barlow LR, Barry RL, Barth M, Battiston M, Büchel C, Budde MD, Callot V, Combes A, De Leener B, Descoteaux M, de Sousa PL, Dostál M, Doyon J, Dvorak AV, Eippert F, Epperson KR, Epperson KS, Freund P, Finsterbusch J, Foias A, Fratini M, Fukunaga I, Gandini Wheeler-Kingshott CAM, Germani G, Gilbert G, Giove F, Grussu F, Hagiwara A, Henry PG, Horák T, Hori M, Joers JM, Kamiya K, Karbasforoushan H, Keřkovský M, Khatibi A, Kim JW, Kinany N, Kitzler H, Kolind S, Kong Y, Kudlička P, Kuntke P, Kurniawan ND, Kusmia S, Laganà MM, Laule C, Law CSW, Leutritz T, Liu Y, Llufriu S, Mackey S, Martin AR, Martinez-Heras E, Mattera L, O'Grady KP, Papinutto N, Papp D, Pareto D, Parrish TB, Pichiecchio A, Prados F, Rovira À, Ruitenberg MJ, Samson RS, Savini G, Seif M, Seifert AC, Smith AK, Smith SA, Smith ZA, Solana E, Suzuki Y, Tackley GW, Tinnermann A, Valošek J, Van De Ville D, Yiannakas MC, Weber KA 2nd, Weiskopf N, Wise RG, Wyss PO, Xu J, Cohen-Adad J, Lenglet C, Nestrašil I. Labounek R, et al. bioRxiv [Preprint]. 2024 May 1:2024.04.29.591421. doi: 10.1101/2024.04.29.591421. bioRxiv. 2024. Update in: Imaging Neurosci (Camb). 2025 May 07;3:imag_a_00559. doi: 10.1162/imag_a_00559. PMID: 38746371 Free PMC article. Updated. Preprint.
Real-World Effectiveness and Safety of Fostamatinib in Difficult-to-Treat Immune Thrombocytopenia Patients. A Prospective, Multicenter Registry in France.
Moulis G, Mahévas M, Viallard JF, Chèze S, Terriou L, Audia S, Moulinet T, Ebbo M, Gobert D, Robbins A, Gourguechon C, Graveleau J, Comont T, Saunier A, Faldlallah J, Carreiro M, Guilpain P, Gil H, Ruivard M, Magy-Bertrand N, Dossier A, Leveneur Y, Delbrel X, Anthony B, Lifermann F, Martin M, Ledoux MP, Roy-Péaud F, Chabbert L, Lapeyre-Mestre M, Sommet A, Zadro Y, Bonnotte B, Michel M, Godeau B; et le groupe des investigateurs de CARMEN‐France. Moulis G, et al. Am J Hematol. 2026 Jan 8. doi: 10.1002/ajh.70194. Online ahead of print. Am J Hematol. 2026. PMID: 41504185
Patients' characteristics, treatment response (ongoing exposure to fostamatinib and a platelet count 30 10(9)/L with no rescue in the previous 4 weeks) after 3, 6, 12, and 24 months (M); bleeding; fostamatinib discontinuation; adverse drug reactions (ADRs) and other events …
Patients' characteristics, treatment response (ongoing exposure to fostamatinib and a platelet count 30 10(9)/L with no rescue in the previo …
Body size and intracranial volume interact with the structure of the central nervous system: A multi-center in vivo neuroimaging study.
Labounek R, Bondy MT, Paulson AL, Bédard S, Abramovic M, Alonso-Ortiz E, Atcheson NT, Barlow LR, Barry RL, Barth M, Battiston M, Büchel C, Budde MD, Callot V, Combes A, De Leener B, Descoteaux M, de Sousa PL, Dostál M, Doyon J, Dvorak AV, Eippert F, Epperson KR, Epperson KS, Freund P, Finsterbusch J, Foias A, Fratini M, Fukunaga I, Wheeler-Kingshott CAMG, Germani G, Gilbert G, Giove F, Grussu F, Hagiwara A, Henry PG, Horák T, Hori M, Joers JM, Kamiya K, Karbasforoushan H, Keřkovský M, Khatibi A, Kim JW, Kinany N, Kitzler H, Kolind S, Kong Y, Kudlička P, Kuntke P, Kurniawan ND, Kusmia S, Laganà MM, Laule C, Law CSW, Leutritz T, Liu Y, Llufriu S, Mackey S, Martin AR, Martinez-Heras E, Mattera L, O'Grady KP, Papinutto N, Papp D, Pareto D, Parrish TB, Pichiecchio A, Prados F, Rovira À, Ruitenberg MJ, Samson RS, Savini G, Seif M, Seifert AC, Smith AK, Smith SA, Smith ZA, Solana E, Suzuki Y, Tackley GW, Tinnermann A, Valošek J, Van De Ville D, Yiannakas MC, Weber Ii KA, Weiskopf N, Wise RG, Wyss PO, Xu J, Cohen-Adad J, Lenglet C, Nestrašil I. Labounek R, et al. Imaging Neurosci (Camb). 2025 May 7;3:imag_a_00559. doi: 10.1162/imag_a_00559. eCollection 2025. Imaging Neurosci (Camb). 2025. PMID: 40800833 Free PMC article.
Optic nerve head vessel density in different stages of pseudoexfoliation disease.
Safizadeh M, Shaabani A, Kamalipour A, Fard MA, Yeh K, Yaseri M, Hamzeh N, Khatibi N, Rao HL, Weinreb R, Moghimi S. Safizadeh M, et al. Br J Ophthalmol. 2022 Feb;106(2):223-228. doi: 10.1136/bjophthalmol-2020-317605. Epub 2020 Nov 27. Br J Ophthalmol. 2022. PMID: 33246938 Free PMC article.
RESULTS: PXG eyes had thinner global RNFL and lower cpCD (74.214.3 m and 36.710.0%) than control (103.38.6 m and 52.52.3%), PXS (96.88.8 m and 51.52.3%), and NL-PXG eyes (96.311.1 m and 50.13.9%) (p<0.001). ...
RESULTS: PXG eyes had thinner global RNFL and lower cpCD (74.214.3 m and 36.710.0%) than control (103.38.6 m and 52.52.3%), PX …
Layer-by-Layer Nanofluidic Membranes for Promoting Blue Energy Conversion.
Khatibi M, Dartoomi H, Ashrafizadeh SN. Khatibi M, et al. Langmuir. 2023 Sep 26;39(38):13717-13734. doi: 10.1021/acs.langmuir.3c01962. Epub 2023 Sep 13. Langmuir. 2023. PMID: 37702658
We solved the steady-state Poisson-Nernst-Planck (PNP) and Navier-Stokes (NS) equations for three different types of nanochannels with a trumpet geometry, where the narrow part is covered with a built-up LbL soft layer and the rest is a hard wall with a surface charge density of …
We solved the steady-state Poisson-Nernst-Planck (PNP) and Navier-Stokes (NS) equations for three different types of nanochannels with a tru …
Green synthesis, characterization, and biological evaluation of gold and silver nanoparticles using Mentha spicata essential oil.
Moosavy MH, de la Guardia M, Mokhtarzadeh A, Khatibi SA, Hosseinzadeh N, Hajipour N. Moosavy MH, et al. Sci Rep. 2023 May 4;13(1):7230. doi: 10.1038/s41598-023-33632-y. Sci Rep. 2023. PMID: 37142621 Free PMC article.
This study investigates the green synthesizing and characterization of gold NPs (AuNPs) and silver NPs (AgNPs) produced using Mentha spicata L. (M. spicata) essential oil as well as their antibacterial, antioxidant, and in vitro cytotoxic effects. ...
This study investigates the green synthesizing and characterization of gold NPs (AuNPs) and silver NPs (AgNPs) produced using Mentha spicata …
Enhanced Ionic Current Rectification through Innovative Integration of Polyelectrolyte Bilayers and Charged-Wall Smart Nanochannels.
Dartoomi H, Khatibi M, Ashrafizadeh SN. Dartoomi H, et al. Anal Chem. 2023 Jan 17;95(2):1522-1531. doi: 10.1021/acs.analchem.2c04559. Epub 2022 Dec 20. Anal Chem. 2023. PMID: 36537870
The maximum rectification of 30.65 was achieved using a nanochannel of type (III) and sigma = +10 mC/m(2). The current results demonstrate a promising hybrid architecture consisting of an LBL soft layer and a smart charged nanochannel for enhanced rectification....
The maximum rectification of 30.65 was achieved using a nanochannel of type (III) and sigma = +10 mC/m(2). The current results demons …
Smart nanochannels: tailoring ion transport properties through variation in nanochannel geometry.
Heydari A, Khatibi M, Ashrafizadeh SN. Heydari A, et al. Phys Chem Chem Phys. 2023 Oct 11;25(39):26716-26736. doi: 10.1039/d3cp03768a. Phys Chem Chem Phys. 2023. PMID: 37779455
The nanochannel with equal cylindrical and conical parts significantly affects conductivity by modifying the charge density in the soft layer, resulting in a 3.125-fold increase in conductivity under positive voltage when the charge density in the polyelectrolyte layer is raised …
The nanochannel with equal cylindrical and conical parts significantly affects conductivity by modifying the charge density in the soft laye …
Ion Transport in Intelligent Nanochannels: A Comparative Analysis of the Role of Electric Field.
Khatibi M, Ashrafizadeh SN. Khatibi M, et al. Anal Chem. 2023 Dec 12;95(49):18188-18198. doi: 10.1021/acs.analchem.3c03809. Epub 2023 Nov 29. Anal Chem. 2023. PMID: 38019778
For instance, under eta(epsilon) = eta(D) = 0.8, eta(mu) = 2, C(0) = 20 mM, and N(PEL)/N(A) = 80 mol m(-3) conditions, the average EOF for conical and cylindrical geometries is 0.1 and 0.008 m/s, respectively. ...
For instance, under eta(epsilon) = eta(D) = 0.8, eta(mu) = 2, C(0) = 20 mM, and N(PEL)/N(A) = 80 mol m(-3) conditions, the average EO …
26 results